Universal Ibogaine Inc. (JC4)
Market Closed
10 Aug, 20:00
XMUN 
€
0. 00
0
0%
€
- Market Cap
- P/E Ratio
- Div Yield
0 Volume
0 Eps
€ 0
Previous Close Want to track JC4 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
JC4 closed yesterday higher at €0, an increase of 0% from Friday's close, completing a monthly increase of 0% or €0. Over the past 12 months, JC4 stock gained 0%.
JC4 is not paying dividends to its shareholders.
The last earnings report, released on Dec 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 4 different exchanges and in various currencies, with the primary listing on TSX-V (CAD).
JC4 Chart
Universal Ibogaine Inc. (JC4) FAQ
What is the stock price today?
The current price is €0.00.
On which exchange is it traded?
Universal Ibogaine Inc. is listed on XMUN.
What is its stock symbol?
The ticker symbol is JC4.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has Universal Ibogaine Inc. ever had a stock split?
No, there has never been a stock split.
Universal Ibogaine Inc. Profile
| Biotechnology Industry | Healthcare Sector | Nicholas Peter Karos CEO | XMUN Exchange | CA91360F1099 ISIN |
| CA Country | 7 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Universal Ibogaine Inc. is positioned as a pioneering life sciences entity with a primary focus on the development, acquisition, and operation of addiction treatment clinics across Canada. With its headquarters nestled in Calgary, Canada, the company is engaged in an ambitious endeavor to harness the therapeutic potential of ibogaine, a naturally occurring psychoactive substance, for addressing various forms of addiction. A key facet of its operations involves conducting meticulously planned clinical trials aimed at investigating ibogaine's effectiveness in addiction treatment, thereby contributing to the broader body of research in this domain and potentially revolutionizing how addiction is treated.
Products and Services
- Addiction Treatment Clinics - Universal Ibogaine Inc. acquires and operates clinics that specialize in the treatment of addiction. These facilities leverage conventional therapeutic modalities alongside innovative approaches to offer comprehensive care tailored to individual patient needs.
- Clinical Trials for Ibogaine Research - At the heart of its research endeavors, the company has undertaken planned clinical trials focused on ibogaine as a treatment for addiction. These trials aim to scientifically assess the efficacy and safety of ibogaine, potentially paving the way for its acceptance and integration into mainstream addiction therapy.
Contact Information
Address: 400 3rd Avenue SW
Phone: 855-426-4246
Website: https://universalibogaine.com
